ViroCell and AvenCell Advance Allogeneic CAR-T Therapy

ViroCell and AvenCell advance allogeneic CAR-T therapy

ViroCell Biologics has partnered AvenCell Therapeutics for development of new allogeneic CAR-T therapies to treat blood cancers.

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development - Pharmafile

ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical development of AVC-203, a new allogeneic CAR-T cell therapy targeting blood cancers and autoimmune diseases. AVC-203 is AvenCell’s second investigational ‘off-the-shelf’ CAR-T product and is engineered to address both graft vs host disease and host […] The post ViroCell Biologics and Aven…

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

Open the article to view the coverage from The AI Journal